Negative control for UNC1666 which is a dual Mer and Flt-3 tyrosine kinase inhibitor

Orally Active Adenosine A 1 Receptor Agonist

Novel Ligand of EEDm acting as an allosteric inhibitor of PRC2

Novel allosteric inhibitor of PRC2 catalytic activity

Novel allosteric inhibitor of PRC2 catalytic activity

Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT

Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

Novel peptidomimetic antagonist of the PHF1 Tudor domain, binding both PHF1 Tudor domain and the related protein PHF19

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

Novel potent and selective PAM of CBX8, blocking H3K27me3 binding and enhancing CBX8 affinity for nucleic acids, evicting PRC1 from H3K27me3 targets triggering DLBCL cell differentiation

Novel β-arrestin-biased D2 receptor (D2R) agonist

Novel Eph antagonist, inhibiting Eph/ephrin interactions, enhancing glucose-stimulated insulin secretion (GSIS), and acting as a hypoglycemic agent

The first bifunctional (chemoreactive and clickable) probe for Adenosine A1 and A3 Receptors

Potent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor

Novel superagonist of the urotensin-II (UT) receptor

Novel Potent antagonist of the Urotensin-II (UT) Receptor

Novel superagonist of the urotensin-II (UT) receptor

Novel potent antagonist of the Urotensin-II (UT) receptor

Novel E-Selectin antagonist, disrupting cell survival pathway activation, enhancing chemotherapy response and protecting from toxicity such as mucositis with improved survival in vivo

Novel Neuropeptide Y Y4 Receptor (Y4R) Antagonist (pK i values <7.57)